Chinese Center for Drug Evaluation (CDE) Cleared Taletrectinib IND and Issued Clinical Trial Authorizations for Two Phase 2 Clinical Trials in China

HANGZHOU, China, March 23, 2020 (GLOBE NEWSWIRE) — AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, today announced that its new drug candidate taletrectinib has received IND clearance and Clinical Trial Authorization (CTA) for its two Phase 2 clinical trials from CDE, the Chinese drug evaluation agency. […]

Research results of AnHeart’s new-generation ROS1/NTRK inhibitor AB-106 published in Nature Communications

Research results of AnHeart’s new-generation ROS1/NTRK inhibitor AB-106 published in Nature Communications   HANGZHOU, Sept. 25 2019 /PRNewswire/ — The preclinical results of AB-106 (original R&D code: DS-6051b), an innovative anti-cancer drug made available exclusively by AnHeart Therapeutics (Hangzhou) Co., Ltd. (”AnHeart”) from Daiichi Sankyo Company Limited, were published online by the peer-reviewed academic journal […]

AnHeart Therapeutics Won the 2019 Sullivan China New Economy

AnHeart Therapeutics Won the 2019 Sullivan China New Economy – Excellence in Innovation Award Frost & Sullivan, the world leading growth consulting company, awarded AnHeart Therapeutics (Hangzhou) Co., Ltd. (“AnHeart”). The 2019 Sullivan China New Economy–Excellence in Innovation Award. AnHeart was selected based on an analysis of the global innovative drug market and evaluation of […]

AnHeart Therapeutics completed 100 million Chinese Yuan Series A round of financing; new anti-cancer drugs to enter China’s clinical trials

On May 15, 2019, AnHeart Therapeutics (Hangzhou) Co., Ltd.. (hereinafter referred to as AnHeart) announced the completion of the series A round of financing raising about 100 million Chinese yuan. The financing was exclusively provided by Decheng Capital, an internationally known venture capital institution specializing in the biomedical industry. This round of financing will be […]

Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics

Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics   TOKYO and BASKING RIDGE, N.J. and NEW YORK, Dec. 17, 2018/PRNewswire/ — Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) and AnHeart Therapeutics Inc. (“AnHeart Therapeutics”) announced they have entered into a worldwide exclusive license agreement (“Agreement”) for DS-6051, Daiichi Sankyo’s selective ROS1/NTRK inhibitor, currently in phase […]

Scroll to top